Melatonin may not help prevent delirium following major cardiac surgery

Delirium is observed in approximately 15% of hospitalized older adults, and it is more common in the critically ill and in those undergoing major surgery, such as heart surgery. Studies have found that blood levels of melatonin, a serotonin-derived hormone, decrease following surgery and are lower in surgical patients who develop delirium. A new study published in the Journal of the American Geriatric Society found that melatonin treatment did not influence the risk of developing delirium following heart surgery, however.

The study included 210 adults aged 50 years or older who were due to undergo major heart surgery. Participants were randomly assigned to seven days of treatment with melatonin or placebo, starting two days prior to the surgery. Patients were then assessed for the development of delirium within seven days of surgery.

A similar proportion of participants experienced severe episodes of delirium in the melatonin and placebo groups.

While the negative findings are disappointing, it is probably not that unexpected given the complex nature of delirium."

Andrew Ford, MBChB, FRANZCP, PhD, lead author from University of Western Australia

Source:
Journal reference:

Ford, A.H., et al. (2019) The Healthy Heart‐Mind Trial: Randomized Controlled Trial of Melatonin for Prevention of Delirium. Journal of the American Geriatrics Society. doi.org/10.1111/jgs.16162.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis